What do systematic reviews say?

Mid‐dose mifepristone (25 mg‐50 mg) vs levonorgestrel 1.5 mg

Mid‐dose mifepristone (25 mg‐50 mg) may leads to lower specific side effect ‐ spotting/bleeding after treatment compared with levonorgestrel 1.5 mg (low certainty).

• Interventions for emergency contraception 2019 · Cochrane Headline outcomes only
  RR 0.61 [0.42, 0.88]
  9 studies · 1796 participants
  Low

Mid‐dose mifepristone (25 mg‐50 mg) vs levonorgestrel 1.5 mg

Mid‐dose mifepristone (25 mg‐50 mg) showed no clear difference in menses ‐ early compared with levonorgestrel 1.5 mg (low certainty).

• Interventions for emergency contraception 2019 · Cochrane Headline outcomes only
  RR 0.72 [0.5, 1.03]
  7 studies · 1324 participants
  Low

Mid‐dose mifepristone (25 mg‐50 mg) vs levonorgestrel 1.5 mg

Mid‐dose mifepristone (25 mg‐50 mg) probably leads to higher menses ‐ delay compared with levonorgestrel 1.5 mg (moderate certainty).

• Interventions for emergency contraception 2019 · Cochrane Headline outcomes only
  RR 1.29 [1.09, 1.54]
  17 studies · 3615 participants
  Moderate

Low‐dose mifepristone (< 25 mg) vs levonorgestrel 1.5 mg

Low‐dose mifepristone (< 25 mg) leads to lower observed number of pregnancies (all women) compared with levonorgestrel 1.5 mg (high certainty).

• Interventions for emergency contraception 2019 · Cochrane Headline outcomes only
  RR 0.72 [0.52, 0.99]
  14 studies · 8752 participants
  High

Low‐dose mifepristone (< 25 mg) vs levonorgestrel 1.5 mg

Low‐dose mifepristone (< 25 mg) may leads to lower any side effect compared with levonorgestrel 1.5 mg (low certainty).

• Interventions for emergency contraception 2019 · Cochrane Headline outcomes only
  RR 0.26 [0.17, 0.38]
  3 studies · 609 participants
  Low

Low‐dose mifepristone (< 25 mg) vs levonorgestrel 1.5 mg

Low‐dose mifepristone (< 25 mg) showed no clear difference in specific side effect ‐ nausea compared with levonorgestrel 1.5 mg (moderate certainty).

• Interventions for emergency contraception 2019 · Cochrane Headline outcomes only
  RR 0.95 [0.84, 1.09]
  5 studies · 6384 participants
  Moderate

Low‐dose mifepristone (< 25 mg) vs levonorgestrel 1.5 mg

Low‐dose mifepristone (< 25 mg) showed no clear difference in specific side effect ‐ vomiting compared with levonorgestrel 1.5 mg (low certainty).

• Interventions for emergency contraception 2019 · Cochrane Headline outcomes only
  RR 1.22 [0.55, 2.68]
  3 studies · 6085 participants
  Low

Low‐dose mifepristone (< 25 mg) vs levonorgestrel 1.5 mg

Low‐dose mifepristone (< 25 mg) leads to lower specific side effect ‐ spotting/bleeding after treatment compared with levonorgestrel 1.5 mg (high certainty).

• Interventions for emergency contraception 2019 · Cochrane Headline outcomes only
  RR 0.61 [0.54, 0.69]
  5 studies · 4598 participants
  High

Low‐dose mifepristone (< 25 mg) vs levonorgestrel 1.5 mg

Low‐dose mifepristone (< 25 mg) may leads to lower menses ‐ early compared with levonorgestrel 1.5 mg (low certainty).

• Interventions for emergency contraception 2019 · Cochrane Headline outcomes only
  RR 0.45 [0.35, 0.59]
  5 studies · 1800 participants
  Low

Low‐dose mifepristone (< 25 mg) vs levonorgestrel 1.5 mg

Low‐dose mifepristone (< 25 mg) may leads to higher menses ‐ delay compared with levonorgestrel 1.5 mg (low certainty).

• Interventions for emergency contraception 2019 · Cochrane Headline outcomes only
  RR 1.7 [1.48, 1.97]
  9 studies · 7520 participants
  Low

Mid‐dose mifepristone (25 mg‐50 mg) vs low‐dose mifepristone (< 25 mg)

Mid‐dose mifepristone (25 mg‐50 mg) leads to lower observed number of pregnancies (all women) compared with low‐dose mifepristone (< 25 mg) (high certainty).

• Interventions for emergency contraception 2019 · Cochrane Headline outcomes only
  RR 0.73 [0.55, 0.97]
  25 studies · 11914 participants
  High

Mid‐dose mifepristone (25 mg‐50 mg) vs low‐dose mifepristone (< 25 mg)

Mid‐dose mifepristone (25 mg‐50 mg) probably leads to higher any side effect compared with low‐dose mifepristone (< 25 mg) (moderate certainty).

• Interventions for emergency contraception 2019 · Cochrane Headline outcomes only
  RR 1.31 [1.01, 1.7]
  11 studies · 2464 participants
  Moderate

Mid‐dose mifepristone (25 mg‐50 mg) vs low‐dose mifepristone (< 25 mg)

Mid‐dose mifepristone (25 mg‐50 mg) showed no clear difference in specific side effects ‐ nausea compared with low‐dose mifepristone (< 25 mg) (moderate certainty).

• Interventions for emergency contraception 2019 · Cochrane Headline outcomes only
  RR 1.1 [0.97, 1.24]
  13 studies · 7948 participants
  Moderate

Mid‐dose mifepristone (25 mg‐50 mg) vs low‐dose mifepristone (< 25 mg)

Mid‐dose mifepristone (25 mg‐50 mg) showed no clear difference in specific side effects ‐ vomiting compared with low‐dose mifepristone (< 25 mg) (moderate certainty).

• Interventions for emergency contraception 2019 · Cochrane Headline outcomes only
  RR 1.22 [0.68, 2.17]
  6 studies · 6082 participants
  Moderate

Mid‐dose mifepristone (25 mg‐50 mg) vs low‐dose mifepristone (< 25 mg)

Mid‐dose mifepristone (25 mg‐50 mg) leads to higher specific side effects ‐ spotting/bleeding after treatment compared with low‐dose mifepristone (< 25 mg) (high certainty).

• Interventions for emergency contraception 2019 · Cochrane Headline outcomes only
  RR 1.85 [1.55, 2.2]
  11 studies · 5078 participants
  High

Mid‐dose mifepristone (25 mg‐50 mg) vs low‐dose mifepristone (< 25 mg)

Mid‐dose mifepristone (25 mg‐50 mg) showed no clear difference in menses ‐ early compared with low‐dose mifepristone (< 25 mg) (low certainty).

• Interventions for emergency contraception 2019 · Cochrane Headline outcomes only
  RR 1.09 [0.87, 1.36]
  7 studies · 2136 participants
  Low

Mid‐dose mifepristone (25 mg‐50 mg) vs low‐dose mifepristone (< 25 mg)

Mid‐dose mifepristone (25 mg‐50 mg) probably leads to higher menses ‐ delay compared with low‐dose mifepristone (< 25 mg) (moderate certainty).

• Interventions for emergency contraception 2019 · Cochrane Headline outcomes only
  RR 1.28 [1.11, 1.47]
  21 studies · 11282 participants
  Moderate

Mid‐dose mifepristone (25 mg‐50 mg) vs levonorgestrel 1.5 mg

Mid‐dose mifepristone (25 mg‐50 mg) probably leads to lower observed number of pregnancies (all women) compared with levonorgestrel 1.5 mg (moderate certainty).

• Interventions for emergency contraception 2019 · Cochrane Headline outcomes only
  RR 0.61 [0.45, 0.83]
  27 studies · 6052 participants
  Moderate

Mid‐dose mifepristone (25 mg‐50 mg) vs levonorgestrel 1.5 mg

Mid‐dose mifepristone (25 mg‐50 mg) may leads to lower any side effect compared with levonorgestrel 1.5 mg (low certainty).

• Interventions for emergency contraception 2019 · Cochrane Headline outcomes only
  RR 0.55 [0.4, 0.74]
  18 studies · 4352 participants
  Low

Augmentation of current antidepressant (various) with cariprazine (1 mg/d to 4.5 mg/d) vs augmentation of current antidepressant (various) with placebo

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 808 participants
  High